Cencora, Inc. (COR)
| Market Cap | 70.19B +40.5% |
| Revenue (ttm) | 325.78B +7.4% |
| Net Income | 1.63B +16.4% |
| EPS | 8.33 +18.6% |
| Shares Out | 194.53M |
| PE Ratio | 43.31 |
| Forward PE | 20.23 |
| Dividend | $2.40 (0.67%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 974,999 |
| Open | 352.66 |
| Previous Close | 349.86 |
| Day's Range | 351.00 - 364.67 |
| 52-Week Range | 237.71 - 377.54 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 395.23 (+9.53%) |
| Earnings Date | Feb 4, 2026 |
About COR
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, ... [Read more]
Financial Performance
In fiscal year 2025, Cencora's revenue was $321.33 billion, an increase of 9.31% compared to the previous year's $293.96 billion. Earnings were $1.55 billion, an increase of 2.99%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for COR stock is "Buy." The 12-month stock price target is $395.23, which is an increase of 9.53% from the latest price.
News
Cencora Closes $3.0 Billion Senior Notes Offering
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, ...
Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the “2029 Notes”)...
Cencora, Inc. (COR) Q1 2026 Earnings Call Transcript
Cencora, Inc. (COR) Q1 2026 Earnings Call Transcript
Cencora beats quarterly profit estimates on strong demand for specialty medicines
Cencora on Wednesday beat Wall Street estimates for first-quarter profit, as the drug distributor rode the wave of sustained demand for specialty medicines and GLP-1 therapies.
Cencora Reports Fiscal 2026 First Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion...
Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products
ATLANTA--(BUSINESS WIRE)--Curant Rare today announced a strategic collaboration with Cencora, a global pharmaceutical solutions organization, that aims to provide pharmaceutical companies developing r...
Cencora Elects Ellen Cooper to Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Ellen Cooper as a new independent director, effective January 20, 2026. Ms. Cooper...
Cencora: High-Growth Specialty Services Firm Disguised As A Distributor
Cencora is transforming from a low-margin distributor to a higher-margin specialty services and oncology-focused business, underrecognized by the market. Cencora's acquisition of OneOncology is a tran...
Cencora, Inc. (COR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Cencora, Inc. (COR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the ope...
Cencora to take majority control of OneOncology to expand cancer services
U.S. drug distributor Cencora said on Monday it will take majority control of cancer care network OneOncology in a deal that values the business at $7.4 billion, as it moves to expand services for com...
Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not cu...
Cencora Enhances Global Pharmaceutical Logistics Services, Cold Chain Capabilities
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced investments to enhance its third-party logistics (3PL) capabilities in the United States and Eur...
Cencora, Inc. (COR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Cencora, Inc. (COR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Cencora, Inc. (COR) Presents at Evercore 8th Annual Healthcare Conference Transcript
Cencora, Inc. (COR) Presents at Evercore 8th Annual Healthcare Conference Transcript
Cencora: Earnings Visibility Driving Re-Rating Potential
Cencora is rated a Buy, with a target price of $392, driven by strong fundamentals and sector leadership. COR's stable business model, high cash flows, low debt, and shareholder-friendly policies make...
Cencora, Inc. (COR) Q4 2025 Earnings Call Transcript
Cencora, Inc. ( COR) Q4 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Bennett Murphy - Senior VP, Head of Investor Relations & Treasury Robert Mauch - President, CEO & Director...
Cencora to invest $1 billion on US drug distribution, posts upbeat 2026 forecast
Cencora will invest over $1 billion through 2030 to expand its U.S. network, the drug distributor said on Wednesday, after forecasting adjusted profit for next year above Wall Street expectations.
Drug Distributor Cencora to Invest $1 Billion in U.S. Supply Chain
The company will open two new distribution centers and expand a third as demand surges for GLP-1s and other refrigerated medications.
Cencora Announces $1 Billion Investment to Strengthen Its U.S. Distribution Network
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced plans to invest $1 billion through 2030 to bolster and expand its pharmaceutical distribution ne...
Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Reven...
ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. The pattern of modest dividend increases continues, with o...
IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina ...
The Market Took a Hit. These 6 Stocks Can Sidestep the Wreckage.
Those looking to buy stocks right now should look for the ones that aren't correlated to the artificial intelligence trade.
Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2025 on Wednesday, November 5, 2025, prior to the op...